查看购物车
  • Traditional Chinese
  • Japanese
封面
市场调查报告书
商品编码
1998487

全球体外诊断试剂盒市场：呼吸系统/非呼吸系统（2020-2030 年）

Worldwide IVD Panel-Based Testing: Respiratory/Non-Respiratory, 2020-2030
出版日期: | 出版商: Kalorama Information | 英文 133 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球呼吸道和非呼吸道体外诊断（IVD）检测组合市场正经历持续的结构性变化。检测组合能够从单一检体同时检测多种病原体和抗药性标记物，从而提高工作流程效率、缩短检测时间并提升诊断可靠性。市场成长日益受到临床应用和各种检测环境中使用量增加的推动。

Kalorama Information 在其报告《全球 IVD 侦测板市场 - 呼吸系统/非呼吸系统（2020-2030 年）》中提供了该市场的分析、估算和预测。

细分市场概览

呼吸道疾病检测组合仍然是检测组合市场的重要组成部分，这得益于其广泛的临床应用和持续的季节性需求。这些检测以多种形式提供，包括分子诊断、免疫检测和照护现场（POC​​）平台，并占据了整体市场收入的相当大份额。

非呼吸道疾病检测组合在检测项目中占比不断成长，并广泛应用于感染疾病和其他专业检测领域。这个细分市场反映了检测项目日益多样化以及基于检测组合的方法在多个检查室环境中的整合应用。

最终用户和医疗保健专业人员

对综合检测的需求主要集中在医院和急诊机构，因为这些机构需要进行多种检测并快速做出临床决策。急诊和重症监护室的检测量占绝大多数，但其他医疗机构也存在非呼吸系统疾病的检测需求。

地理范围

北美地区拥有成熟的市场基础和完善的诊断基础设施，是呼吸系统和非呼吸系统体外诊断试剂盒检测的最大区域市场。 《2020-2030年全球体外诊断试剂盒检测—呼吸系统/非呼吸系统》报告也分析了欧洲、亚太地区和世界其他地区，提供了全球市场展望。

调查方法

本报告从製造商层级分析了全球体外诊断试剂盒市场，涵盖了多个技术类别的呼吸系统和非呼吸系统检测。

  • 分子
  • 免疫检测
  • 护理点
  • 核心检查室
  • 组织病理学
  • 免疫血液学

市场数据涵盖2020年至2030年，以2025年为基准年，并计算了2025年至2030年预测期的复合年增长率（CAGR）。报告包含区域和终端用户分析，预测基于人口趋势、技术创新、新产品开发和全球扩张。

研究结果是基于广泛的一手和二手资料研究，包括对行业高管、顾问、医疗保健专业人员和政府相关人员的采访，并得到了对公司文件、资料库、投资报告以及医学和商业期刊的分析的支持。

目录

第一章执行摘要

第二章：引言

  • 概述
  • 体外诊断（IVD）临床检测组的类型
    • 感染疾病检测组
    • 专门针对感染疾病的小型检测小组
    • 抗菌素抗药性（AMR）检测组
    • 肿瘤基因组（NGS）检测组
    • STI面板
    • 基因和遗传疾病检测
    • 产前检测项目
    • 挑战与趋势
    • 多重检测费用报销
    • 体外诊断多重检测法规概述
    • 多重体外诊断检测的优势
    • 临床意义及过度检查的挑战

第三章：分子体外诊断试剂盒检测

  • 介绍
  • 终端用户市场：分子体外诊断试剂盒
  • 呼吸技术专家组
    • 分子呼吸系统体外诊断试剂盒检测
    • 呼吸系统临床适应小组
    • 症状性性行为感染呼吸道病原体检测
    • 针对特定族群的迷你和组合呼吸道检测板
    • 实验室分子检测板市场
  • 非呼吸技术小组
    • 分子感染疾病（非呼吸系统）多重检测
    • 血流（量）
    • 性行为感染感染（STI）
    • 肝炎
    • 验血
    • 其他的
    • 分子检测及其他非呼吸道疾病检测
    • 肿瘤学
    • 基因
    • 组织类型鑑定
    • 区域市场概览

第四章：体外免疫检测组合

  • 介绍
  • 终端用户市场：免疫检测体外诊断试剂盒
  • 呼吸技术专家组
    • 免疫检测组合板
  • 非呼吸技术小组
    • 采用免疫检测法进行非呼吸道感染疾病多重检测
    • 血流（量）
    • 性行为感染感染（STI）
    • 肝炎
    • 火炬
    • 血库筛检
    • 用于体外诊断其他非呼吸系统疾病的多重免疫检测法检测板
    • 过敏
    • 自体免疫
    • 甲状腺
    • 药物毒理学与滥用
    • 其他免疫检测组（不包括呼吸系统）
    • 区域市场概览

第五章：照护现场（POC​​）体外诊断试剂盒考试

  • 介绍
  • 终端用户市场：照护现场试剂盒
  • 呼吸技术专家组
    • 即时免疫检测组
    • 即时分子呼吸道检测板
  • 非呼吸技术小组
    • 照护现场（POC​​）非呼吸道感染疾病检测
    • 性行为感染传染病
    • 肝炎
    • 其他感染疾病
    • 照护现场（POC​​）非呼吸系统及其他体外诊断试剂盒检测
    • 重症监护
    • 血液学
    • 脂质
    • 毒理学/药物滥用
    • 尿液检查
    • 其他的
  • 区域市场概览

第六章：核心实验室小组考试

  • 介绍
  • 终端用户市场：CoreLab IVD 面板
  • 普通化学体外诊断试剂盒检测
  • 血液气体外诊断试剂盒检测
  • 尿液检查IVD 检测
  • 血液学体外诊断试剂盒检测
  • 区域市场概览

第七章：解剖病理学检查

  • 介绍
  • 终端用户市场：解剖病理学体外诊断试剂盒
  • 区域市场概览

第八章 免疫血液学检测

  • 介绍
  • 终端用户市场：免疫血液学体外诊断试剂盒
  • 区域市场概览

第九章 体外诊断（IVD）检测的市场小组分析

  • 整体市场
    • 呼吸系统体外诊断试剂盒市场
    • 非呼吸道病原体检测板体外诊断检测市场
  • 目标市场
    • 呼吸系统
    • 感染疾病（非呼吸道）
    • 血液感染疾病/院内感染/败血症
    • 性行为感染传染病
    • 肝炎
    • 血库筛检
    • ToRCH
    • 其他（非呼吸系统）体外​​诊断测试组也包含在内。
  • 按最终用户分類的市场分布
    • 医院检查室
    • 急诊（ER）/紧急护理室（UC）
    • 独立/参考测试机构
    • 诊所
    • 非处方药/零售/其他
  • 区域市场
    • 北美洲
    • 欧洲
    • 亚太地区
    • 其他地区
简介目录
Product Code: 26-033KA

The global market for respiratory and non-respiratory IVD panel-based testing is undergoing continued structural evolution. Panel-based tests allow for the simultaneous detection of multiple pathogens and or resistance markers from a single specimen, supporting efficient workflows, faster time to results, and greater diagnostic confidence. Market growth is increasingly driven by broader clinical adoption and expanding use across a range of testing environments.

Kalorama Information analyzes, estimates, and forecasts this market in Worldwide IVD Panel-Based Testing: Respiratory/Non-Respiratory, 2020-2030.

Segment Landscape

Respiratory panels remain an important component of the panel-based testing market, supported by widespread clinical use and recurring seasonal demand. These tests are offered across multiple formats, including molecular, immunoassay, and point-of-care platforms, and represent a meaningful share of overall market revenues.

Non-respiratory panels account for a growing portion of panel-based testing and span a range of applications, including infectious disease and other specialized testing areas. This segment reflects increasing test menu diversity and the integration of panel-based approaches across multiple laboratory settings.

End Users and Care Settings

Demand for panel-based testing is concentrated in hospital and acute care environments, where broad test menus and rapid clinical decision-making are essential. Emergency and urgent care settings contribute significant testing volumes, while additional utilization occurs across other care settings for non-respiratory applications.

Geographic Scope

North America is the largest regional market for respiratory and non-respiratory IVD panel-based testing, supported by a well-established installed base and mature diagnostic infrastructure. Worldwide IVD Panel-Based Testing: Respiratory/Non-Respiratory, 2020-2030 also examines Europe, Asia Pacific, and the Rest of the World to provide a global market perspective.

Scope and Methodology

This report analyzes the global IVD panel-based testing market at the manufacturer level, covering both respiratory and non-respiratory tests across multiple technology categories:

  • Molecular
  • Immunoassay
  • Point-of-care
  • Core laboratory
  • Anatomic pathology
  • Immunohematology

Market data spans 2020 through 2030, with 2025 as the base year and CAGR calculations provided for the 2025 to 2030 forecast period. Regional and end-user analyses are included, with forecasts informed by demographic trends, technological innovation, new product development, and global expansion.

Research findings are based on extensive primary and secondary research, including interviews with industry executives, consultants, healthcare providers, and government personnel, supported by analysis of company materials, databases, investment reports, and medical and business journals.

Table of Contents

Chapter 1: Executive Summary

  • About Kalorama Information
  • Industry at a Glance
  • Scope and Methodology
  • Size and Growth of the Market
    • Table 1-1: Total IVD Panel Market, 2020-2030 ($ million)
    • Figure 1-1: Total IVD Panel Market, 2020-2030 ($ million)
  • Key Issues and Trends Affecting the Market
  • Conclusion Highlights

Chapter 2: Introduction

  • Overview
  • IVD Clinical Panel Types
    • Infectious Disease Syndromic Panels
    • Targeted Infectious Disease Mini-Panels
    • Antimicrobial Resistance (AMR) Panels
    • Oncology Genomic (NGS) Panels
    • STI Panels
    • Genetic and Inherited Disease Panels
    • Prenatal Panels
    • Issues and Trends
    • Reimbursement for Multiplex Tests
    • IVD Multiplex Regulatory Overview
    • Advantages of Multiplex IVD Testing
    • Clinical Relevance and Over-Testing Challenges

Chapter 3: Molecular IVD Panel-Based Tests

  • Introduction
    • Table 3-1: Molecular IVD Panel-Based Tests, Overall Segment Revenue, 2020-2030 ($ million)
    • Figure 3-1: Molecular IVD Panel-Based Tests, Respiratory/Non-Respiratory Revenue, 2020-2030 ($ million)
    • Figure 3-2: Molecular IVD Panel-Based Tests, Respiratory/Non-Respiratory Revenue Distribution, 2025 (%)
  • End User Market: Molecular IVD Panels
    • Figure 3-3: End User Revenue Source Distribution: Molecular IVD Panel-Based Tests, 2025 (%) [Emergency and Acute Care Units, Hospital Laboratories, Independent and Reference Laboratories, Physician Offices]
  • Respiratory Technology Panels
    • Molecular Respiratory IVD Panel-Based Tests
    • Respiratory Clinical Indication Panels
    • Syndromic Infectious Disease Respiratory Panels
    • Targeted Mini and Combo Respiratory Panels
    • Lab-based Molecular Panel Market
      • Table 3-2: Lab-based Molecular Respiratory IVD Panel-Based Tests, 2025-2030 ($ million)
      • Figure 3-4: Lab-based Molecular Respiratory IVD Panel-Based Tests, 2020-2030 ($ million)
      • Figure 3-5: Lab-based Molecular Respiratory IVD Panel-Based Tests, Distribution by Type, 2025 (%) [Syndromic, Combo/Mini]
  • Non-Respiratory Technology Panels
    • Molecular Infectious Disease (Non-Respiratory) Multiplex Panels
      • Table 3-3: Molecular Non-Respiratory Infectious Disease Panel-Based Tests, Overall Market, 2025-2030 ($ million)
      • Figure 3-6: Molecular Non-Respiratory Infectious Disease Panel-Based Tests, by Type, 2020-2030 ($ million) [Blood Bank Screening; Bloodstream Infection, HAI, Sepsis, STI; Hepatitis; Other Infectious Disease]
    • Bloodstream
      • Table 3-4: Molecular Bloodstream Non-Respiratory Infectious Disease Panel-Based Tests, 2025-2030 ($ million)
    • Sexually Transmitted Infections (STI)
      • Table 3-5: Molecular Sexually Transmitted Infection (STI) Non-Respiratory Infectious Disease Panel-Based Tests, 2025-2030 ($ million)
    • Hepatitis
      • Table 3-6: Molecular Hepatitis Non-Respiratory Infectious Disease Panel-Based Tests, 2025-2030 ($ million)
    • Blood Screening
      • Table 3-7: Molecular Blood Screening Non-Respiratory Infectious Disease Panel-Based Tests, 2025-2030 ($ million)
    • Other
      • Table 3-8: Other Molecular Non-Respiratory Infectious Disease Panel-Based Tests, 2025-2030 ($ million)
    • Molecular and Other Non-Respiratory Panel-Based Tests
      • Table 3-9: Molecular and Other Non-Respiratory IVD Panel-Based Tests, Overall Market, 2025-2030 ($ million)
      • Figure 3-7: Molecular and Other Non-Respiratory IVD Panel-Based Tests, 2020-2030 ($ million) [Genetic, Oncology, Tissue Typing]
    • Oncology
      • Table 3-10: Molecular Oncology IVD Panel-Based Tests, 2025-2030 ($ million)
    • Genetic
      • Table 3-11: Molecular Genetic IVD Panel-Based Tests, 2025-2030 ($ million)
    • Tissue Typing
      • Table 3-12: Molecular Tissue Typing IVD Panel-Based Tests, 2025-2030 ($ million)
    • Geographic Market Overview
      • Table 3-13: Regional Summary - Molecular IVD Panels, 2025-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
      • Figure 3-8: Regional Summary - Molecular IVD Panels, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]

Chapter 4: Immunoassay IVD Panel-Based Tests

  • Introduction
    • Table 4-1: Immunoassay IVD Panel-Based Tests, Overall Segment Revenue, 2020-2030 ($ million)
    • Figure 4-1: Immunoassay IVD Panel-Based Tests (Respiratory, Non-Respiratory), 2020-2030 ($ million)
    • Figure 4-2: Immunoassay IVD Panel-Based Tests, Respiratory/Non-Respiratory Revenue Distribution, 2025 (%)
  • End User Market: Immunoassay IVD Panels
    • Figure 4-3: End User Revenue Source Distribution, Immunoassay IVD Panel-Based Tests, 2025 (%) [Emergency and Acute Care Units, Hospital Laboratories, Independent and Reference Laboratories, Physician Offices]
  • Respiratory Technology Panels
    • Immunoassay Combo Panels
      • Table 4-2: Immunoassay Respiratory IVD Panel-Based Tests, 2025-2030 ($ million)
      • Figure 4-4: Immunoassay Respiratory IVD Panel-Based Tests, 2020-2030 ($ million)
  • Non-Respiratory Technology Panels
    • Immunoassay Non-Respiratory Infectious Disease Multiplex Panels
      • Table 4-3: Immunoassay Non-Respiratory Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
      • Figure 4-5: Immunoassay Non-Respiratory Infectious Disease IVD Panel-Based Tests, by Type, 2020-2030 ($ million) [Blood Bank Screening; Bloodstream, HAI, Sepsis; Hepatitis; STI; ToRCH; Other]
    • Bloodstream
      • Table 4-4: Bloodstream Immunoassay Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
    • Sexually Transmitted Infections (STI)
      • Table 4-5: Sexually Transmitted Infections (STI) Immunoassay Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
    • Hepatitis
      • Table 4-6: Hepatitis Immunoassay Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
    • ToRCH
      • Table 4-7: ToRCH Infectious Disease IVD Immunoassay Panel-Based Tests, 2025-2030 ($ million)
    • Blood Bank Screening
      • Table 4-8: Blood Bank Infectious Disease Screening Immunoassay IVD Panel-Based Tests, 2025-2030 ($ million)
    • Immunoassay Other Non-Respiratory Disease IVD Multiplex Panels
      • Table 4-9: Immunoassay and Other Non-Respiratory Disease IVD Multiplex Panel-Based Tests, 2025-2030 ($ million)
    • Allergy
      • Table 4-10: Allergy Immunoassay Panel-Based Tests, 2025-2030 ($ million)
    • Autoimmune
      • Table 4-11: Autoimmune Immunoassay Panel-Based Tests, 2025-2030 ($ million)
    • Thyroid
      • Table 4-12: Thyroid Immunoassay Panel-Based Tests, 2025-2030 ($ million)
    • Toxicology and Drugs of Abuse
      • Table 4-13: Toxicology and Drugs of Abuse Immunoassay Panel-Based Tests, 2025-2030 ($ million)
    • Other Immunoassay Panels (Non-Respiratory)
      • Table 4-14: Other Immunoassay Panel-Based Tests, 2025-2030 ($ million)
      • Figure 4-6: Immunoassay Non-Respiratory Other IVD Panel-Based Tests, by Type, 2020-2030 ($ million) [Allergy, Autoimmune, Thyroid, Toxicology/Drugs of Abuse, Other]
    • Geographic Market Overview
      • Table 4-15: Immunoassay Panel-Based Tests, Geographic Markets, 2025-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
      • Figure 4-7: Regional Summary: Immunoassay IVD Panels, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]

Chapter 5: Point-of-Care (POC) IVD Panel-Based Tests

  • Introduction
    • Table 5-1: POC IVD Panel-Based Tests, Overall Segment Revenue, 2020-2030 ($ million)
    • Figure 5-1: POC IVD Panel-Based Tests, by Segment, 2020-2030 ($ million) [Respiratory, Non-Respiratory]
    • Figure 5-2: POC IVD Panel-Based Tests, Respiratory/Non-Respiratory Revenue Distribution, 2025 (%)
  • End User Market: Point-of-Care IVD Panels
    • Figure 5-3: End User Revenue Source Distribution: POC IVD Panel-Based Tests, 2025 (%) [Emergency and Acute Care Units, Hospital Laboratories, OTC and Retail Settings, Physician Offices]
  • Respiratory Technology Panels
    • POC Immunoassay Respiratory Panels
      • Table 5-2: POC Immunoassay Respiratory Panel-Based Tests, 2025-2030 ($ million)
    • POC Molecular Respiratory Panels
      • Table 5-3: POC Molecular Respiratory Panel-Based Tests, 2025-2030 ($ million)
      • Figure 5-4: POC Respiratory IVD Panel-Based Tests, 2020-2030 ($ million) [Immunoassay/Molecular]
  • Non-Respiratory Technology Panels
    • POC Non-Respiratory Infectious Disease Panel-Based Tests
      • Figure 5-5: POC Non-Respiratory Infectious Disease IVD Panel-Based Tests, 2020-2030 ($ million) [Hepatitis, STI, Other]
    • Sexually Transmitted Infections
      • Table 5-4: POC Sexually Transmitted Infection (STI) Non-Respiratory Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
    • Hepatitis
      • Table 5-5: POC Hepatitis Non-Respiratory Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
    • Other Infectious Diseases
      • Table 5-6: POC Other Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
    • POC Non-Respiratory Other IVD Panel-Based Tests
      • Table 5-7: POC Non-Respiratory Other IVD Panel-Based Tests, 2025-2030 ($ million)
      • Figure 5-6: POC Other Non-Respiratory IVD Panel-Based Tests, 2020-2030 ($ million) [Critical Care, Hematology, Lipid, Tox/Drug of Abuse, Urinalysis, Other]
    • Critical Care
      • Table 5-8: POC Critical Care IVD Panel-Based Tests, 2025-2030 ($ million)
    • Hematology
      • Table 5-9: POC Hematology IVD Panel-Based Tests, 2025-2030 ($ million)
    • Lipid
      • Table 5-10: POC Lipid IVD Panel-Based Tests, 2025-2030 ($ million)
    • Toxicology/Drugs of Abuse
      • Table 5-11: POC Toxicology/Drugs of Abuse IVD Panel-Based Tests, 2025-2030 ($ million)
    • Urinalysis
      • Table 5-12: POC Urinalysis IVD Panel-Based Tests, 2025-2030 ($ million)
    • Other
      • Table 5-13: POC Other IVD Panel-Based Tests, 2025-2030 ($ million)
  • Geographic Market Overview
    • Table 5-14: POC IVD Panels, Geographic Markets, 2025-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
    • Figure 5-7: Regional Summary - POC IVD Panels, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]

Chapter 6: Core Laboratory Panel-Based Tests

  • Introduction
    • Table 6-1: Core Lab IVD Panel-Based Tests, Overall Segment Revenue, 2020-2030 ($ million)
    • Figure 6-1: Core Lab IVD Panel-Based Tests, 2020-2030 ($ million)
  • End User Market: Core Lab IVD Panels
    • Figure 6-2: End User Revenue Source Distribution: Core Lab IVD Panel-Based Tests, 2025 (%) [Emergency and Acute Care Units, Hospital Laboratories, Independent and Reference Laboratories, OTC and Retail Settings, Physician Offices]
  • General Chemistry IVD Panel-Based Tests
    • Table 6-2: General Chemistry IVD Panel-Based Tests, 2020-2030 ($ million)
    • Figure 6-3: General Chemistry IVD Panel Summary, 2020-2030 ($ million)
  • Blood Gases IVD Panel-Based Tests
    • Table 6-3: Blood Gases IVD Panel-Based Tests, 2020-2030 ($ million)
    • Figure 6-4: Blood Gases IVD Panel Summary, 2020-2030 ($ million)
  • Urinalysis IVD Panel-Based Tests
    • Table 6-4: Urinalysis IVD Panel-Based Tests, 2020-2030 ($ million)
    • Figure 6-5: Urinalysis IVD Panel Summary, 2020-2030 ($ million)
  • Hematology IVD Panel-Based Tests
    • Table 6-5: Hematology IVD Panel-Based Tests, 2020-2030 ($ million)
    • Figure 6-6: Hematology IVD Panel Summary, 2020-2030 ($ million)
  • Geographic Market Overview
    • Table 6-6: Core Lab IVD Panels, Geographic Markets, 2025-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
    • Figure 6-7: Regional Summary - Core Lab IVD Panels, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]

Chapter 7: Anatomic Pathology Panel-Based Tests

  • Introduction
    • Table 7-1: Anatomic Pathology IVD Panel-Based Tests, Overall Segment Revenue, 2020-2030 ($ million)
    • Figure 7-1: Anatomic Pathology IVD Panel-Based Tests, 2020-2030 ($ million)
  • End User Market: Anatomic Pathology IVD Panels
    • Figure 7-2: End User Revenue Source Distribution: Anatomic Pathology IVD Panel-Based Tests, 2025 (%) [Emergency and Acute Care Units, Hospital Laboratories, Independent and Reference Laboratories, Physician Offices]
  • Geographic Market Overview
    • Table 7-2: Anatomic Pathology Panel-Based Tests, Geographic Markets, 2025-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
    • Figure 7-3: Regional Summary - Anatomic Pathology IVD Panels, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]

Chapter 8: Immunohematology Panel-Based Tests

  • Introduction
    • Table 8-1: Immunohematology IVD Panel-Based Tests, 2020-2030 ($ million)
    • Figure 8-1: Immunohematology IVD Panel-Based Tests, 2020-2030 ($ million)
  • End User Market: Immunohematology IVD Panels
    • Figure 8-2: End User Revenue Source Distribution: Immunohematology IVD Panel-Based Tests, 2025 (%) [Emergency and Acute Care Units, Hospital Laboratories, Independent and Reference Laboratories, Physician Offices]
  • Geographic Market Overview
    • Table 8-2: Immunohematology Panel-Based Tests, Geographic Markets, 2025-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
    • Figure 8-3: Regional Summary - Immunohematology IVD Panels, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]

Chapter 9: Market Panel-Based IVD Testing Analysis

  • Total Market
    • Table 9-1: Total IVD Panel Market, by Segment, 2020-2030 ($ million) [Anatomic Pathology, Core Laboratory, Immunoassay, Immunohematology, Molecular, Point-of-Care]
    • Figure 9-1: Total Panel-Based IVD Testing Market-Respiratory/Non-Respiratory, 2020-2030 ($ million)
    • Figure 9-2: Total Global Panel-Based IVD Testing Market-Respiratory/Non-Respiratory-Revenue Distribution, 2025 (%)
    • Respiratory IVD Panel-Based Testing Market
      • Table 9-2: Total Respiratory IVD Panel Market, 2020-2030 ($ million) [Immunoassay, Molecular, Point-of-Care]
      • Figure 9-3: Total Respiratory IVD Panel Market, 2020-2030 ($ million) [Immunoassay, Molecular, Point-of-Care]
    • Non-Respiratory Panel-Based IVD Testing Market
      • Table 9-3: Total Non-Respiratory IVD Panel Market, 2020-2030 ($ million)
      • Figure 9-4: Total Non-Respiratory IVD Panel Market, 2020-2030 ($ million) [Anatomic Pathology, Core Lab, Immunoassay, Immunohematology, Molecular, POC]
  • Market by Target
    • Respiratory
      • Table 9-4: Respiratory IVD Panels, 2020-2030 ($ million)
      • Figure 9-5: Respiratory IVD Panels, 2020-2030 ($ million)
    • Infectious Disease (Non-Respiratory)
      • Table 9-5: Infectious Disease Non-Respiratory Panel-Based Tests, Overall Market, 2025-2030 ($ million)
    • Bloodstream/HAI/Sepsis
      • Table 9-6: Bloodstream/HAI/Sepsis IVD Panels, 2020-2030 ($ million)
      • Figure 9-6: Bloodstream/HAI/Sepsis IVD Panels, 2020-2030 ($ million)
    • Sexually Transmitted Infections
      • Table 9-7: Sexually Transmitted Infection (STI) IVD Panels, 2020-2030 ($ million)
      • Figure 9-7: Sexually Transmitted Infection (STI) IVD Panels, 2020-2030 ($ million)
    • Hepatitis
      • Table 9-8: Hepatitis IVD Panels, 2020-2030 ($ million)
      • Figure 9-8: Hepatitis IVD Panels, 2020-2030 ($ million)
    • Blood Bank Screening
      • Table 9-9: Blood Bank Screening IVD Panels, 2020-2030 ($ million)
      • Figure 9-9: Blood Bank Screening IVD Panels, 2020-2030 ($ million)
    • ToRCH
      • Table 9-10: ToRCH IVD Panels, 2020-2030 ($ million)
      • Figure 9-10: ToRCH IVD Panels, 2020-2030 ($ million)
    • Other (Non-Respiratory) IVD Panel Targets
      • Table 9-11: Other, Non-Respiratory IVD Panel Targets, 20205-2030 ($ million)
      • Table 9-12: Other, Non-Respiratory IVD Panel Targets, by Type, 2025, ($ million) [Allergy, Autoimmune, Blood Gases + Critical Care, Blood Grouping/Typing, Genetic + Prenatal Testing, General Chemistry, Hematology, Immunohistochemistry (IHC), Lipid (Cholesterol), Oncology, Thyroid, Tissue Typing, Toxicology/Drugs of Abuse, Urinalysis, Other]
      • Figure 9-11: Other, Non-Respiratory IVD Panel Targets, by Type, 2025, ($ million) [Allergy, Autoimmune, Blood Gases + Critical Care, Blood Grouping/Typing, Genetic + Prenatal Testing, General Chemistry, Hematology, Immunohistochemistry (IHC), Lipid (Cholesterol), Oncology, Thyroid, Tissue Typing, Toxicology/Drugs of Abuse, Urinalysis, Other]
  • Market by End-User Distribution
    • Figure 9-12: Total Global Panel-Based IVD Testing Market, By End User, 2020-2030 ($ million) [Emergency/UC, Hospital, Independent/Reference, OTC/Retail, Physician Office]
    • Figure 9-13: Total Panel-Based IVD Testing Market, By End User, Revenue Distribution, 2025 (%) [Emergency/UC, Hospital, Independent/Reference, OTC/Retail, Physician Office]
    • Hospital Lab
      • Table 9-13: Hospital Lab IVD Panel-Based Test Revenue, 2025-2030 ($ million)
    • Emergency (ER)/Urgent Care (UC)
      • Table 9-14: Emergency (ER)/Urgent Care (UC) IVD Panel-Based Test Revenue, 2025-2030 ($ million)
    • Independent/Reference Lab
      • Table 9-15: Independent/Reference Lab IVD Panel-Based Test Revenue, 2025-2030 ($ million)
    • Physician Office
      • Table 9-16: Physician Office IVD Panel-Based Test Revenue, 2025-2030 ($ million)
    • OTC/Retail/Others
      • Table 9-17: OTC/Retail/Other IVD Panel-Based Test Revenue, 2025-2030 ($ million)
  • Market by Region
    • Figure 9-14: Total Panel-Based IVD Testing Market, By Geographic Region, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
    • Figure 9-15: Total Panel-Based IVD Testing Market, By Geographic Region, Revenue Distribution, 2025 (%) [Asia Pacific, Europe, North America, RoW]
    • North America
      • Table 9-18: North America - IVD Panel-Based Test Revenue, 2025-2030 ($ million)
      • Figure 9-16: North America - IVD Panel Market, 2020-2030 ($ million) [Anatomic Pathology, Core Lab, Immunoassay, Immunohematology, Molecular, POC]
    • Europe
      • Table 9-19: Europe - IVD Panel-Based Test Revenue, 2025-2030 ($ million)
      • Figure 9-17: Europe - IVD Panel Market, 2020-2030 ($ million) [Anatomic Pathology, Core Lab, Immunoassay, Immunohematology, Molecular, POC]
    • Asia Pacific
      • Table 9-20: Asia Pacific - IVD Panel-Based Test Revenue, 2025-2030 ($ million)
      • Figure 9-18: Asia Pacific - IVD Panel Market, 2020-2030 ($ million) [Anatomic Pathology, Core Lab, Immunoassay, Immunohematology, Molecular, POC]
    • RoW
      • Table 9-21: Rest of World - IVD Panel-Based Test Revenue, 2025-2030 ($ million)
      • Figure 9-19: Rest of World - IVD Panel Market, 2020-2030 ($ million) [Anatomic Pathology, Core Lab, Immunoassay, Immunohematology, Molecular, POC]